Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma

S. Brugnatelli, A. Riccardi, G. Ucci, O. Mora, L. Barbarano, N. Piva, L. Piccinini, C. Bergonzi, A. De Paoli, M. Di Stasi, E. Rinaldi, G. Trotti, M. Petrini, E. Ascari

Research output: Contribution to journalArticlepeer-review


In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-α2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

Original languageEnglish
Pages (from-to)794-797
Number of pages4
JournalBritish Journal of Cancer
Issue number6
Publication statusPublished - 1996


  • Advanced myeloma
  • Cyclophosphamide
  • Epirubicin
  • Outpatient therapy
  • Randomisation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma'. Together they form a unique fingerprint.

Cite this